Atlas Trials

Sheng Tai

1 clinical trials · Sponsor

Sort:Newest firstOldest first

◉ Watch Sheng Tai

RecordFirmDate
Multi-Omics-Based Phase Ⅱ Trial of Trastuzumab Rezetecan Plus Camrelizumab for Perioperative Therapy in HER2-Positive Muscle-Invasive Urothelial Carcinoma (NCT07639983)Sheng Tai2026-06-05

Track Sheng Tai automatically

Every clearance here is in the API, with alerts when new ones post.